Skip to main content

Table 1 Literature review of all clinical cases to date

From: ALK-rearranged lung squamous cell carcinoma responding to alectinib: a case report and review of the literature

Authors Age (y) Sex Method of diagnosis and/or type of tissue sampled ALK detection Smoking history (pack-years) Prior treatment ALK inhibitor Efficacy
Wang et al. [9] 55 F Biopsy of the cervical lymph node IHC, FISH Non-smoker PDC Crizotinib PR
Mikes et al. [10] 36 M Bronchial biopsy of the primary lesion IHC, FISH, RT-PCR Non-smoker None Crizotinib PR
Zhang et al. [11] 55 F Bronchial biopsy of the primary lesion IHC Non-smoker PDC Crizotinib PR
Vergne et al. [12] 58 F Bronchial biopsy IHC, FISH Non-smoker PDC Crizotinib PR
Tamiya et al. [13] 78 M Primary lesion IHC, FISH 49 None Alectinib PD
This case 52 F Bronchial biopsy of the mediastinal lymph node IHC, FISH Non-smoker PDC Alectinib PR
  1. ALK anaplastic lymphoma kinase, F female, FISH fluorescence in situ hybridization, IHC immunohistochemistry, M male, PCR polymerase chain reaction, PD progressive disease, PDC platinum-doublet chemotherapy, PR partial response, RT reverse transcription, y year